The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | BTK inhibitor-associated adverse events in patients with CLL
Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, discusses BTK inhibitor-related adverse events in patients with chronic lymphocytic leukemia (CLL), comparing the toxicity profiles of non-specific BTK inhibitors and next-generation BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Dr Eichhorst receives honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).
